The trial data presented in Chicago, Illinois, this year at the 2016 meeting of the American Society of Clinical Oncology (ASCO) are going to change daily clinical practice for the treatment of patients with gliomas. The first of 3 practice-changing reports was from the European Organisation for Research and Treatment of Cancer (EORTC) randomized phase III CATNON (Trial 26054)1 for adult patients with newly diagnosed anaplastic gliomas without codeletion of 1p/19q in the tumor tissue.
